Takeda Pharmaceutical Company Limited (TSE:4502) exercised an option to acquire Adaptate Biotherapeutics Ltd from Abingworth LLP on January 10, 2022. The acquisition is subject to completion of review under applicable antitrust laws, including the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 in the U.S. The acquisitions of Adaptate is expected to be finalised in first quarter of Takeda's fiscal year 2022.